ArticleEuropean journal of nuclear medicine and molecular imaging2022
Assessment of malignancy and PSMA expression of uncertain bone foci in [
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria.European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic Accuracy of [Cancers · 2026Article
- Comparison of urinary bladder activity from [EJNMMI reports · 2026Article
- Assessing the frequency and accuracy of morphologic changes of focal bone lesions on [European journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.Skeletal radiology · 2025Article
- Unspecific bone uptakes in PSMA PET for prostate cancer: why do they matter?European radiology · 2025Article
- [European journal of nuclear medicine and molecular imaging · 2025Article
- How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View.European urology open science · 2025Article
- Review
- The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review.Cancers · 2025Review
- The impact of long axial field of view (LAFOV) PET on oncologic imaging.European journal of radiology · 2025Review
- Focal Unspecific Bone Uptake on [Diagnostics (Basel, Switzerland) · 2024Article
- Rate of unspecific bone uptake on PSMA PET is determined by the Scaffold - not the Radionuclide. Letter regarding: "The homunculus of unspecific bone uptakes associated with PSMA- targeted tracers: a systematic review-based definition" and "Cutting back on overdiagnosis - Occam's razor and unspecific bone uptakes in PSMA PET".European journal of nuclear medicine and molecular imaging · 2024Article
- Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features?Cancers · 2023Article
- Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.European urology · 2023Article
- Management of bone metastasis in prostate cancer.Journal of bone and mineral metabolism · 2023Review
- Multiparametric dynamic whole-body PSMA PET/CT using [EJNMMI research · 2023Article
- Predicting Outcomes of Indeterminate Bone Lesions onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are frequently observed in patients undergoing [
methodsA retrospective analysis revealed 10 patients who were referred to our department for PET-guided biopsy of UBU visible in a previous [
resultsOne out of 11 (9.1%) of the foci biopsied was confirmed as bone metastasis of PC with intense PSMA-expression, while 10/11 (90.9%) foci were revealed to be unremarkable bone tissue without evidence of PSMA expression at IHC. Amongst all bone foci assessed by biopsy, eight were visually classified as being at high risk of malignancy in the PET/CT (SUVmean 12.0 ± 8.1; SUVmax 18.8 ± 13.1), three as equivocal (SUVmean 4.6 ± 2.1; SUVmax 7.2 ± 3.0) and zero as low risk. No UBU had any CT correlate.
conclusionsThis cohort biopsy revealed that a small but relevant number of UBU are true metastases. For those confirmed as benign, no PSMA expression at IHC was observed, suggesting a non-PSMA mediated cause for intensive [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.